Palvella Therapeutics (PVLA) Accounts Payables (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Accounts Payables data on file, last reported at $5.4 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $5.4 million, up 22.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.4 million (up 22.56% YoY), and the FY2025 annual result was $4.6 million, changed 0.2% from the prior year.
• Accounts Payables grew to $5.4 million in Q1 2026 per PVLA's latest filing, from $4.6 million in the prior quarter.
• Over five years, Accounts Payables peaked at $14.1 million in Q1 2022 and troughed at $801000.0 in Q3 2024.
• A 5-year average of $4.7 million and a median of $4.4 million in 2025 frame the typical range for Accounts Payables.
• On a YoY basis, Accounts Payables climbed as much as 389.96% in 2024 and fell as far as 87.26% in 2024.
• A 5-year view of Accounts Payables shows it stood at $4.2 million in 2022, then tumbled by 77.47% to $936000.0 in 2023, then surged by 389.96% to $4.6 million in 2024, then advanced by 0.2% to $4.6 million in 2025, then climbed by 18.45% to $5.4 million in 2026.
• Business Quant data shows PVLA's Accounts Payables at $5.4 million in Q1 2026, $4.6 million in Q4 2025, and $3.5 million in Q3 2025.